Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Oragenics, Inc.
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
March 14, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
March 08, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
March 01, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Regains Compliance with NYSE American
February 03, 2023
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
December 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
December 22, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Receives NYSE American Notice
December 20, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Announces New Chair
December 19, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Participate in the 2022 BioFlorida Annual Conference
October 24, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Issues Letter to Shareholders
September 30, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
August 24, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
June 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Issues Letter to Shareholders
May 17, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Participate at the World Vaccine Congress Washington 2022
April 18, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
April 06, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
March 25, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
March 22, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
January 26, 2022
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
December 20, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners
December 09, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics
December 08, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
December 01, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
November 23, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.
October 04, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
September 15, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants
August 30, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Postponement of Annual Meeting of Shareholders
August 24, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines
July 27, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
July 01, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Oragenics Issues Letter to Shareholders
May 18, 2021
From
Oragenics, Inc.
Via
Business Wire
Tickers
OGEN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.